Dysmenorrhea Drug Pipeline Market Report 2022: Assessment by Product Type, Stage, Route of Administration, and Molecule Type - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Dysmenorrhea - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
This "Dysmenorrhea - Pipeline Insight, 2022" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Dysmenorrhea pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Dysmenorrhea Emerging Drugs Chapters
This segment of the Dysmenorrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dysmenorrhea Emerging Drugs
Pelubiprofen - Daewon Pharmaceutical
Pelubiprofen is a cyclooxygenase 2 (COX-2) inhibitor approved for the treatment of osteoarthritis and back pain. It is currently in phase III stage of development for Primary Dysmenorrhea.
PNB 001: PNB Vesper Life Science
PNB 001 is being developed by PNB Vesper Life Science for the treatment of Dysmenorrhoea. PNB-001 is an isoform-selective antagonist that binds to CCK2 at 20 nM. In an isolated tissue assay, using CCK-5 as agonist the antagonizing properties were confirmed. L-365,260 was used as best CCK2 gastrin antagonist standard and PNB-001 was 10 times more potent and of much higher magnitude. It is currently in phase I stage of development.
Dysmenorrhea: Therapeutic Assessment
This segment of the report provides insights about the different Dysmenorrhea drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Dysmenorrhea
There are approx. 3+ key companies which are developing the therapies for Dysmenorrhea. The companies which have their Dysmenorrhea drug candidates in the most advanced stage, i.e. phase III include Daewon Pharmaceutical and others
The report covers around 3+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Dysmenorrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Gene therapies
- Small molecule
- Monoclonal antibodies
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Dysmenorrhea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dysmenorrhea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dysmenorrhea drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Dysmenorrhea R&D. The therapies under development are focused on novel approaches to treat/improve Dysmenorrhea.
- Intellectual property of PNB-001 and structurally related molecules are well protected with patents filed in the US, Europe, and rest of the World. USPTO has issued the patent on December 28, 2014.
Dysmenorrhea Report Insights
- Dysmenorrhea Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Dysmenorrhea Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
- Daewon Pharmaceutical
- PNB Vesper Life Science Nobelpharma
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/hh3wpg
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900